BJDX news

Bluejay Diagnostics released preliminary clinical data from the SYMON-II study supporting the Symphony IL-6 test's potential for mortality risk assessment in sepsis, marking a key milestone toward regulatory submission.

Bluejay Diagnostics completed enrollment in its SYMON-II study testing Symphony IL-6 for sepsis mortality risk ahead of plan, potentially supporting future regulatory filings and commercialization.

The company's Board approved Amendment No. 1 to its 2021 Stock Plan on April 28, 2026, with stockholder approval on June 9, 2026. The amendment modifies the equity compensation framework for key employees, directors, and consultants.

Bluejay Diagnostics filed a pre-funded common stock purchase warrant form exercisable for shares at a future price. The unregistered securities offering allows existing investors to purchase common stock at minimal upfront cost under terms outlined in a June 2, 2026 purchase agreement.

Bluejay Diagnostics entered into a manufacturing agreement with Argonaut Manufacturing Services for reservoir fill and seal production, effective May 27, 2026. The partnership includes technology transfer, quality management, validation services, and supply chain support for diagnostic product manuf…